JP2024508045A - ホスホイノシチド3キナーゼベータ阻害剤ならびにそれらの組成物および方法 - Google Patents
ホスホイノシチド3キナーゼベータ阻害剤ならびにそれらの組成物および方法 Download PDFInfo
- Publication number
- JP2024508045A JP2024508045A JP2023571435A JP2023571435A JP2024508045A JP 2024508045 A JP2024508045 A JP 2024508045A JP 2023571435 A JP2023571435 A JP 2023571435A JP 2023571435 A JP2023571435 A JP 2023571435A JP 2024508045 A JP2024508045 A JP 2024508045A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- morpholino
- mmol
- group
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163144287P | 2021-02-01 | 2021-02-01 | |
| US63/144,287 | 2021-02-01 | ||
| PCT/US2022/013725 WO2022164812A1 (en) | 2021-02-01 | 2022-01-25 | Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024508045A true JP2024508045A (ja) | 2024-02-21 |
| JP2024508045A5 JP2024508045A5 (cg-RX-API-DMAC7.html) | 2025-01-21 |
Family
ID=82654889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571435A Pending JP2024508045A (ja) | 2021-02-01 | 2022-01-25 | ホスホイノシチド3キナーゼベータ阻害剤ならびにそれらの組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240166617A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4284375A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024508045A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240016938A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117615763A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022214080A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3209581A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL304895A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022164812A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3217937A1 (en) | 2021-05-03 | 2022-11-10 | Erin Danielle ANDERSON | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease |
| MX2023013987A (es) | 2021-05-27 | 2024-02-12 | Petra Pharma Corp | Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento contra el cáncer. |
| TW202329930A (zh) | 2021-09-30 | 2023-08-01 | 美商佩特拉製藥公司 | 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑 |
| US20260130925A1 (en) * | 2022-10-14 | 2026-05-14 | Genesis Molecular Ai, Inc. | Methods for treating cancer |
| EP4602043A1 (en) * | 2022-10-14 | 2025-08-20 | Genesis Therapeutics, Inc. | 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer |
| EP4680612A1 (en) * | 2023-03-15 | 2026-01-21 | AN2 Therapeutics, Inc. | Chemical compounds |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003530318A (ja) * | 2000-01-24 | 2003-10-14 | キネイシア ピーティーワイ リミテッド | モルホリノ置換化合物治療薬 |
| JP2006500361A (ja) * | 2002-08-16 | 2006-01-05 | キネイシア ピーティーワイ リミテッド | ホスホイノシチド3−キナーゼβの阻害 |
| WO2008148074A2 (en) * | 2007-05-24 | 2008-12-04 | Research Foundation Of State University Of New York | Inhibitors of mtor and methods of treatment using same |
| JP2013508449A (ja) * | 2009-10-27 | 2013-03-07 | アストラゼネカ アクチボラグ | 抗腫瘍活性があるクロメノン誘導体 |
-
2022
- 2022-01-25 CN CN202280017243.9A patent/CN117615763A/zh active Pending
- 2022-01-25 EP EP22746472.4A patent/EP4284375A4/en active Pending
- 2022-01-25 WO PCT/US2022/013725 patent/WO2022164812A1/en not_active Ceased
- 2022-01-25 IL IL304895A patent/IL304895A/en unknown
- 2022-01-25 CA CA3209581A patent/CA3209581A1/en active Pending
- 2022-01-25 JP JP2023571435A patent/JP2024508045A/ja active Pending
- 2022-01-25 KR KR1020237029259A patent/KR20240016938A/ko active Pending
- 2022-01-25 US US18/273,634 patent/US20240166617A1/en active Pending
- 2022-01-25 AU AU2022214080A patent/AU2022214080A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003530318A (ja) * | 2000-01-24 | 2003-10-14 | キネイシア ピーティーワイ リミテッド | モルホリノ置換化合物治療薬 |
| JP2006500361A (ja) * | 2002-08-16 | 2006-01-05 | キネイシア ピーティーワイ リミテッド | ホスホイノシチド3−キナーゼβの阻害 |
| WO2008148074A2 (en) * | 2007-05-24 | 2008-12-04 | Research Foundation Of State University Of New York | Inhibitors of mtor and methods of treatment using same |
| JP2013508449A (ja) * | 2009-10-27 | 2013-03-07 | アストラゼネカ アクチボラグ | 抗腫瘍活性があるクロメノン誘導体 |
Non-Patent Citations (2)
| Title |
|---|
| J. MED. CHEM., vol. 57, JPN6025043539, 2014, pages 903 - 920, ISSN: 0005870967 * |
| J. MED. CHEM., vol. 58, JPN6025043538, 2015, pages 943 - 962, ISSN: 0005719873 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022164812A1 (en) | 2022-08-04 |
| US20240166617A1 (en) | 2024-05-23 |
| CA3209581A1 (en) | 2022-08-04 |
| AU2022214080A1 (en) | 2023-09-14 |
| EP4284375A1 (en) | 2023-12-06 |
| CN117615763A (zh) | 2024-02-27 |
| IL304895A (en) | 2023-10-01 |
| KR20240016938A (ko) | 2024-02-06 |
| EP4284375A4 (en) | 2025-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102249236B1 (ko) | Pi3k 억제제로서 헤테로시클릴아민 | |
| AU2014324595B2 (en) | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
| TW202328124A (zh) | 1,4-氧雜氮雜環庚烷衍生物及其用途 | |
| EP4284375A1 (en) | Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof | |
| JP6873977B2 (ja) | 三環式pi3k阻害化合物及び使用方法 | |
| CA3289215A1 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| AU2017279014A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| KR20130116358A (ko) | Pi3 키나아제 억제제로서 헤테로사이클릭 화합물 | |
| IL259843A (en) | Methods for treating Huntington's disease | |
| EA036172B1 (ru) | Спирогептансалициламиды и родственные соединения как ингибиторы rock | |
| CA2809836A1 (en) | Pyridinones/pyrazinones, method of making, and method of use thereof for the treatment of disorders mediated by bruton's tyrosine kinase | |
| AU2011249912A1 (en) | Pyridone and aza-pyridone compounds and methods of use | |
| AU2012332368A1 (en) | Alkylated piperazine compounds as inhibitors of Btk activity | |
| KR20120034607A (ko) | 이미다조〔2,1-b〕〔1,3,4〕티아디아졸 유도체 | |
| WO2023006013A1 (zh) | 新型parp7抑制剂及其应用 | |
| JP2022547777A (ja) | ヒダントイン誘導体 | |
| CA3231988A1 (en) | Azaindazole macrocycle compound and use thereof | |
| CN120574242A (zh) | 含嘧啶多元并环类衍生物抑制剂、其制备方法和应用 | |
| KR20230104782A (ko) | Bcr-abl 티로신 키나제 억제용 7-아자인돌 화합물 | |
| CN115916771B (zh) | 多靶点的抗肿瘤化合物及其制备方法和应用 | |
| WO2019166639A1 (en) | Substituted benzodiazoles and use thereof in therapy | |
| TW202214634A (zh) | 雜環化合物及其衍生物 | |
| CN116964046B (zh) | Plk4抑制剂及其用途 | |
| CN115677682B (zh) | 螺环类plk4抑制剂及其用途 | |
| CA3259052A1 (en) | HETEROCYCLIC COMPOUNDS USED AS PI3K.ALPHA INHIBITORS. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250110 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250110 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20251016 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251029 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260114 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260310 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260527 |